Myomo's core business model centers on a proprietary myoelectric upper-limb orthosis, with revenue driven by direct device sales enabled by recent Medicare Part B reimbursement expansion. The technology and reimbursement position are defensible and differentiated within a niche medical robotics mar…
Myomo (MYO) Q4 2024: 154% Revenue Surge and First Positive Operating Cash Flow Marks Market Inflection
Myomo achieved a transformational inflection in Q4 2024, driven by Medicare Part B reimbursement expansion, doubling unit volume and delivering positive operating cash flow for the first time. The company’s strategic investments in capacity and channel development underpin a robust growth outlook with 2025 revenue guidance of $50 million to $53 million. Execution on multi-channel expansion and payer engagement will be critical to sustaining momentum and scaling profitably.
Summary
- Medicare Reimbursement Catalysis: Expanded Medicare Part B coverage unlocked access to half the addressable market, accelerating patient adoption and revenue growth.
- Operational Scaling and Efficiency: Manufacturing capacity more than doubled, with substantial clinical training of prosthetists expanding distribution channels.
- Growth and Profitability Trajectory: First positive operating cash flow achieved; 2025 guidance targets 54% to 66% revenue growth with investments weighted toward the second half.
Business Overview
Myomo, Inc. is a wearable medical robotics company specializing in powered upper-limb orthoses designed to restore arm and hand function for patients with neurological disorders or paralysis. The core product, MyoPro, utilizes proprietary myoelectric control to translate patients’ own neural signals into motor assistance, enabling activities of daily living. Revenue is primarily generated through direct sales of MyoPro units to patients, with key segments including direct provider channels, orthotics and prosthetics (O&P) clinics, and international distributors.
Performance Analysis
In the fourth quarter of 2024, Myomo delivered record revenue of $12.1 million, representing a 154% increase year-over-year, fueled by a 106% rise in unit sales to 220 devices and a 23% increase in average selling price (ASP) to approximately $54,900. Medicare Part B patients accounted for 57% of revenue, reflecting successful market penetration following CMS’s expanded reimbursement policy effective April 2024. Gross margin improved to 71.4%, benefiting from higher ASP and better fixed cost absorption as volume scaled.
Operating expenses grew 60% year-over-year to $8.9 million, driven by increased headcount to support engineering, clinical, and reimbursement functions, alongside incentive compensation accruals. Despite higher expenses, operating loss narrowed sharply to $0.2 million from $2.4 million in the prior year quarter. Adjusted EBITDA turned positive for the first time at approximately $0.2 million, underscoring operational leverage. The patient pipeline expanded 33% to 1,389 candidates, with record quarterly additions of 657, signaling strong top-of-funnel momentum.
- Revenue Unit Growth: Doubling of unit deliveries evidences effective commercialization post-Medicare expansion.
- Margin Expansion: ASP uplift and volume-driven overhead absorption improved gross margin by over 600 basis points.
- Cash Flow Milestone: First positive operating cash flow of $3.4 million achieved, supporting financial sustainability.
This quarter marks a pivotal inflection in Myomo’s growth trajectory, transitioning from investment to scalable revenue generation and cash flow positive operations.
Executive Commentary
"Our success in the fourth quarter is the culmination of a transformational year for Myomo, as quarterly revenue surpassed $12 million, with double the unit volume compared to the prior year period and generating positive quarterly cash flows. We rapidly scaled our operations to serve the Medicare Part B population that is medically eligible to receive a MyoPro. We exited the year in the best position we've been in, and our objective is to repeat our success from this year in 2025."
Paul R. Gudonis, Chief Executive Officer
"A highlight for the quarter was achieving positive adjusted EBITDA, which we reached for the first time in our history. Adjusted EBITDA was about $200,000, a significant improvement compared with a negative $2.1 million for the fourth quarter of 2023. Cash provided by operating activities was $3.4 million for the fourth quarter of 2024, the first positive quarterly cash flow from operations in the Company's history."
Dave Henry, Chief Financial Officer
Strategic Positioning
1. Medicare Part B Reimbursement as a Growth Catalyst
The April 2024 CMS decision to cover MyoPro under Medicare Part B expanded Myomo’s addressable market by approximately 50%. This regulatory milestone enabled direct billing to a large, previously inaccessible patient base, accelerating revenue and unit growth. The company’s focus on educating this segment and streamlining clinical pathways supports sustainable demand growth.
2. Multi-Channel Commercial Expansion
Myomo is scaling both its direct provider model and the orthotics and prosthetics (O&P) clinic channel. The latter saw a 94% sequential revenue increase in Q4 and benefits from 160 certified prosthetists trained in 2024, exceeding initial targets. This channel leverages established clinical networks for broader patient reach, expected to contribute meaningfully to 2025 revenue.
3. Operational Capacity and Infrastructure Investments
The company relocated to a larger 35,000 square foot facility in Burlington, MA, and more than doubled manufacturing capacity to 120 units per month. Headcount increased by 100 employees in 2024, with further hiring planned to support clinical, manufacturing, and reimbursement functions, underpinning scalable growth.
4. International Expansion Focused on Germany
International revenue, primarily from Germany, reached over $1 million in Q4 and $4 million for the full year. The German market benefits from statutory health insurance coverage and a growing network of over 100 trained O&P partners. Myomo plans to continue investing in this market while deferring broader international expansion due to regulatory and reimbursement complexities.
5. Payer Contracting and Reimbursement Advocacy
Myomo has secured or is finalizing contracts with five new payers, covering approximately 18.6 million lives, facilitating in-network status and more predictable revenue cycles. Despite progress, challenges persist with Medicare Advantage and some commercial payers, requiring ongoing appeals and advocacy to improve coverage and reduce denials.
Key Considerations
Myomo’s Q4 performance reflects a company successfully transitioning from early-stage commercialization to scalable operations, yet execution risks remain.
- Pipeline Depth and Lead Generation: The patient pipeline grew 33%, but sustained growth depends on effective marketing spend and maintaining cost efficiency in patient acquisition.
- Reimbursement Complexity: While Medicare Part B coverage is strong, ongoing denial rates and slow appeals in Medicare Advantage pose headwinds to revenue visibility and timing.
- Channel Development Balance: The direct provider channel remains dominant, but O&P clinics are an emerging growth lever requiring continued training and operational support.
- Margin Sustainability: Gross margin gains from higher ASP and volume absorption are positive, but increased overhead from facility and staffing expansions may temper margin expansion.
- Cash Flow Management: Positive cash flow in Q4 is a key milestone, but 2025 investments in advertising and personnel will pressure cash flow until revenue growth materializes fully.
Risks
Myomo faces risks from reimbursement uncertainties, particularly with Medicare Advantage and commercial payers, which could delay or reduce revenue recognition. Operational scaling challenges, including supply chain disruptions or slower-than-expected O&P channel adoption, could constrain growth. Regulatory changes or tariff fluctuations, while currently minimal, remain potential cost pressures.
Forward Outlook
For Q1 2025, Myomo expects revenue between $9.0 million and $9.5 million, reflecting typical seasonality but representing a 140% to 153% increase year-over-year. Full-year 2025 guidance anticipates revenue of $50 million to $53 million, a 54% to 66% increase over 2024. Management plans to nearly double advertising spend to over $6 million to fuel pipeline growth, with revenue weighted toward the second half of the year. Operating cash flow is expected to be negative in the first three quarters, with a return to positive cash flow targeted for Q4 2025.
Takeaways
Myomo’s Q4 2024 results and 2025 guidance signal a company at a critical inflection point, leveraging regulatory breakthroughs and operational scale to drive growth and approach profitability.
- Medicare Part B Reimbursement Unlocks Market Potential: The expanded coverage has doubled unit volume and increased revenue visibility, providing a strong foundation for scaling.
- Channel Diversification and Capacity Buildout Support Growth: Investments in manufacturing, clinical training, and payer contracting position Myomo to expand reach and improve delivery efficiency.
- Execution on Pipeline Development and Payer Engagement Will Determine Momentum: Maintaining efficient patient acquisition and navigating reimbursement complexities are critical to achieving 2025 financial targets and sustainable profitability.
Conclusion
Myomo’s fourth quarter demonstrated the tangible benefits of strategic focus on Medicare Part B reimbursement and operational scale, delivering record revenue and positive operating cash flow. The company’s ambitious 2025 growth plan is supported by expanding channels and increased marketing investments, though execution risks remain. Investors should monitor pipeline growth, reimbursement progress, and margin trends as key indicators of sustained momentum.
Industry Read-Through
Myomo’s success underscores the importance of regulatory clarity and reimbursement access in emerging medical robotics markets, particularly for neuromuscular rehabilitation devices. The company’s multi-channel approach, combining direct provider sales with clinic partnerships, offers a replicable model for scaling adoption in niche medical device categories. Challenges with Medicare Advantage and commercial payer denials reflect broader healthcare reimbursement complexities that other medtech companies must navigate. The positive margin and cash flow trajectory signal that operational scale can be achieved in this high-touch, customized device market, providing a benchmark for peers targeting similar patient populations.